The largest insider buys this week were Kinder Morgan Inc. (KMI, Financial), Biomarin Pharmaceutical Inc. (BMRN, Financial), Quidel Corp. (QDEL, Financial) and American Financial Group Inc. (AFG, Financial).
Kinder Morgan director bought 7,000 shares
Director William A. Smith bought 7,000 shares of Kinder Morgan on Aug. 31 for an average price of $13.96. The share price has decreased by 3.15% since then.
Kinder Morgan is an American energy infrastructure company that specializes in owning and controlling oil and natural gas pipelines and terminals. Currently, the company is the largest energy infrastructure company in North America and operates approximately 84,000 miles of pipelines and owns about 180 terminals. The company has a market capitalization of $30.6 billion; as of Sept. 4, it traded at $13.52.
On July 22, Kinder Morgan announced that the board of directors declared a cash dividend of 26.25 cents per share for the second quarter of 2020, representing a 5% increase over the second quarter of 2019. The dividend was paid on Aug. 17 to shareholders of record at the close of business on Aug. 3.
Biomarin Pharmaceutical director bought 12,800 shares
Director David E. I. Pyott bought 12,800 shares of Biomarin on Aug. 31 for an average price of $78.26. The stock has declined 2.89% since then.
BioMarin Pharmaceutical is an American biotechnology company that focuses on enzyme replacement therapies. The company was the first to provide therapeutics for mucopolysaccharidosis type I by manufacturing laronidase. The company was also the first to provide therapeutics for phenylketonuria. The company has a market capitalization of $13.78 billion; as of Sept. 4, it traded at $76.
On Aug. 20, BioMarin Pharmaceutical announced it has submitted a New Drug Application to the U.S. Food and Drug Administration for vosoritide, an investigational injection analog of C-type Natriuretic Peptide for children with achondroplasia. The company also announced that the European Medicines Agency validated the company's Marketing Authorization Application for vosoritide on Aug. 13.
Quidel director bought 7,700 shares
Director Matthew Strobeck bought 7,700 shares of Quidel on Sept. 3 for an average price of $166.07. Since then, the share price has decreased 7.02%.
Quidel is an international pharmaceutical company that focuses on manufacturing and developing diagnostic health care products. The company is also a component of the S&P 400. The company has a market capitalization of $6.48 billion; as of Sept. 4, it traded at $154.41.
On Aug. 20, Quidel announced it has completed its investigation regarding a report of false positives at a testing location in Vermont. The company found no testing site or product related issues with the Sofia 2 instrument or the Sofia SARS Antigen FIA. This was in response to complaints of false positive results among patients who were subsequently tested and found negative by PCR testing.
American Financial Group director bought 3,000 shares
Director Kenneth C. Ambrecht bought 3,000 shares of American Financial Group on Sept. 1 for an average price of $66.38. The stock has increased by 3.39% since then.
American Financial Group a financial services holding company that focuses on insurance and investments. The company's subsidiaries include Great American Custom, Mid-Continent Group, National Interstate and Republic Indemnity. The company is also a component of the S&P 400. The company has a market capitalization of $6.08 billion; as of Sept. 4, it traded at $68.63.
On Aug. 31, American Financial Group announced that Brian S. Hertzman has been promoted to senior vice president and chief financial officer. Hertzman joined the company in 1991 and previously served as vice president and controller, responsible for oversight of accounting policies and procedures in compliance with GAAP and other applicable regulations.
For the complete list of stocks that were bought by their company executives, go to Insider Trades.
Disclosure: I do not own stock in any of the companies mentioned in the article.
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
